Outcomes of leadless pacing with the Micra VR beyond 10 years

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Pacing indications (e.g., atrial fibrillation with slow ventricular conduction, sinus node dysfunction, AV block) (n=65). Intervention: Micra VR leadless pacemaker. Primary outcome: Device extractions, revisions, or replacements.

Constanze Puschmann; Hermann Blessberger; Justin Lacher; Hannah Rohringer; Jakob Bötscher; Julian Maier; Michael Gundendorfer; Stefan Schwarz; Christian Reiter; Jörg Kellermair; Juergen Kammler; Thomas Lambert; Karim Saleh; Clemens Steinwender

doi:10.1093/europace/euag271

October 1, 2026EP EuropaceOpen Access

Outcomes of leadless pacing with the Micra VR beyond 10 years

View Full Paper

Ask AI

Bookmark

Share

Key result

Micra VR shows sustained 10-year stability with zero device revisions, extractions, or replacements.

n=65

Key Points

To evaluate clinical outcomes, electrical performance, and battery longevity exceeding 10 years in patients receiving a Micra VR leadless pacemaker.
Retrospective single-centre study of consecutive patients (N=65 analyzed, median age 80.6 years) implanted with a Micra VR leadless pacemaker between December 2013 and September 2015 in Austria.
Electrical parameters (R-wave amplitude, pacing threshold, impedance) were assessed at implant, 1-year follow-up, and last interrogation over a median follow-up of 5 years (range 3.0 months–11.3 years).
Device interrogation, battery voltage, and estimated remaining longevity were analyzed in a subset of patients with more than 10 years of follow-up (n=14).
Pacing thresholds remained stable from implantation to last follow-up (median 0.40 V vs. 0.50 V, P=0.181), while R-wave amplitude increased (10.5 mV to 15.6 mV, P<0.001) and impedance decreased (680 Ω to 530 Ω, P<0.001).
Zero device infections, device malfunctions, revisions, extractions, or replacements occurred during follow-up across all 65 patients.
Among 14 patients evaluated beyond 10 years, estimated remaining battery longevity varied widely from 0.25 to 7.0 years, driven by individual pacing burden and pacing threshold.

Study Design

Type

Cohort (n=65)

Multicenter

No

PICO

P

Population

65 adults with standard pacing indications who received a Micra VR leadless pacemaker, followed for a median of 5 years with a subset of 14 patients evaluated beyond 10 years.

I

Intervention / Comparator

Micra VR leadless pacemaker

O

Primary Outcome

Device extractions, revisions, or replacements

Limitations

Small sample size for the >10 year subgroup (n = 14)
Single-centre design
Survivor bias inherent to a first-in-human cohort

Implication

Retrospective cohort study reveals stable electrical performance and variable battery longevity of leadless pacemakers beyond 10 years, highlighting the need for individualized monitoring.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Puschmann et al. (2026) conducted a cohort in Pacing indications (e.g., atrial fibrillation with slow ventricular conduction, sinus node dysfunction, AV block) (n=65). Micra VR leadless pacemaker was evaluated on Device extractions, revisions, or replacements. In a first-in-human cohort, the Micra VR leadless pacemaker demonstrated sustained electrical stability for over 10 years with 0% of patients requiring device extraction, revision, or replacement.

synapsesocial.com/papers/6acb11ae22e5745bb069e249 https://doi.org/10.1093/europace/euag271

View Full Paper

Ask AI

Bookmark

Share

Outcomes of leadless pacing with the Micra VR beyond 10 years

Key Points

Study Design

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Outcomes of leadless pacing with the Micra VR beyond 10 years

Key Points

Study Design

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading